CAJ | 학술논문

目的：评价阿德福韦对比恩替卡韦治疗慢性乙型病毒性肝炎（乙肝）的临床疗效及安全性。方法86例慢性乙肝患者随机分为阿德福韦组（41例）和恩替卡韦组（45例），分别口服阿德福韦0．5 mg? d－1和恩替卡韦10 mg? d－1，疗程均为12个月。比较2组患者治疗前后乙肝病毒（ HBV） DNA载量、病毒转阴率及药品不良反应。结果治疗12个月后，阿德福韦组与恩替卡韦组患者HBV DNA病毒载量[（4．21±0．71） vs （4．01±0．68）log10 copies? mL－1]较治疗前均明显降低，差异有统计学意义（ P＜0．05）。2组HBV DNA转阴率及谷丙转氨酶（ALT）正常率差异无统计学意义（P＞0．05）。2组患者不良反应发生率差异无统计学意义（ P＞0．05）。结论阿德福韦与恩替卡韦治疗慢性乙肝均有较好的临床疗效，且不良反应轻微。
목적：평개아덕복위대비은체잡위치료만성을형병독성간염（을간）적림상료효급안전성。방법86례만성을간환자수궤분위아덕복위조（41례）화은체잡위조（45례），분별구복아덕복위0．5 mg? d－1화은체잡위10 mg? d－1，료정균위12개월。비교2조환자치료전후을간병독（ HBV） DNA재량、병독전음솔급약품불량반응。결과치료12개월후，아덕복위조여은체잡위조환자HBV DNA병독재량[（4．21±0．71） vs （4．01±0．68）log10 copies? mL－1]교치료전균명현강저，차이유통계학의의（ P＜0．05）。2조HBV DNA전음솔급곡병전안매（ALT）정상솔차이무통계학의의（P＞0．05）。2조환자불량반응발생솔차이무통계학의의（ P＞0．05）。결론아덕복위여은체잡위치료만성을간균유교호적림상료효，차불량반응경미。
Objective To evaluate the clinical efficacy and safety of adefovir and entecavir in the treatment of chronic hepatitis B ( CHB ) . Methods Eighty -six patients with CHB were recruited from 2012 to 2013 in our hospital and randomly divided into adefovir group ( n=41 ) and entecavir group ( n=45 ) .Patients in the adefovir group and ente-cavir group were given adefovir 0.5 mg? d-1 , po and entecavir 10 mg? d-1 , po, respectively.The treatment lasted for 12 months.The he-patitis B virus( HBV) DNA, HBV negative rate and adverse drug reac-tions in two groups were compared before and after treatment.Results After 12 months treatment, the HBV DNA were significantly decreased in both groups [ ( 4.21 ±0.71 ) vs ( 4.01 ±0.68 ) log10 copies? mL-1 ] with statistical difference ( P <0.05 ) , but no statistical difference in HBV negative rate and ALT normal rate was found between the two groups ( P>0.05 ) .Conclusion Significant clinical efficacy of both adefovir and entecavir was found in the treatment of chronic hepatitis B, with less adverse drug reactions.